Received Jun 15, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | 1 | Z012120 | — |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | 2 | Z012120 | — |
he patient has not reported any symptoms. No additional AE; The patient was then given Merck VARIVAX again on 05/30/2026 in (withheld country).; a patient received VARIVAX in the United States 3 weeks after being given a dose of MMR in (withheld country); This spontaneous report was received from a physician and refers to a 5-year-old patient of unknown gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 07-Apr-2026, the patient was vaccinated with Measles vaccine; Mumps vaccine;Rubella vaccine (with Tresivac) (lot #0135AB199, expiration date: Mar-2028) for prophylaxis in (country withheld). Later, on 28-Apr-2026, the patient was vaccinated with Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX), (lot #Z012120, expiration date: 23-Jul-2027), 0.5 mL (strength and anatomical location not provided) for prophylaxis and diluted with sterile diluent 0.7 mL (lot # and expiration date were not reported) (Inappropriate schedule of vaccine administered). On 30-May-2026, the patient received Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX), (lot #Z012120, expiration date: 23-Jul-2027), 0.5 mL (strength and anatomical location not provided) for prophylaxis and diluted with sterile diluent (lot #Z013233, expiration date: 07-Jul-2028) prefilled syringe, 0.7 mL (anatomical location not provided) (Inappropriate schedule of vaccine administered). The patient had not reported any symptoms.
DILUENT MRK